Asher Biotherapeutics

Asher Bio is developing a new generation of immunotherapies using its proprietary cis-targeting platform, which aims to solve the fundamental challenge of selectivity by engaging both an immunomodulatory receptor and a specific surface marker on the same target cell. The company's lead program, etakafusp alfa, has demonstrated proof of mechanism and early anti-tumor activity in an ongoing Phase 1a/1b trial, validating the platform. With a pipeline extending into infectious diseases and a focus on strategic collaborations, Asher Bio is positioned to expand the therapeutic potential of immunomodulators across multiple indications.

Proprietary cis-targeting platform that creates bispecific immunotherapies requiring binding to both an immunomodulatory receptor and a specific cell-surface marker on the same target cell, enabling unprecedented cellular selectivity for cytokines and other immunomodulators.

Asher Bio competes with companies developing engineered IL-2 variants and cytokine mimetics, such as Neoleukin/Bicycle, Sanofi, Alkermes/Mural Oncology, and Werewolf Therapeutics. Its key differentiation is the cis-targeting mechanism, which imposes a cellular context requirement for activation rather than solely engineering the cytokine's receptor affinity, aiming for superior cellular selectivity as evidenced by early clinical data.